AstraZeneca’s COPD drug Fasenra fails to meet primary endpoint in phase III trial

This article was originally published here

AstraZeneca’s respiratory drug Fasenra (benralizumab) has failed to meet its primary endpoint in the Galathea phase III trial.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply